Article Information
History
- June 19, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Jienchi Dorward1,2,*,
- Yukteshwar Sookrajh3,
- Richard Lessells2,4,
- Elliot Bulo3,
- Nicola Bodley2,
- Lavanya Singh4,
- Pravikrishnen Moodley5,
- Natasha Samsunder2,
- Paul K. Drain6,7,8,
- Gail Hayward1,
- Christopher C Butler1 and
- Nigel Garrett2,9
- 1Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
- 2Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu–Natal, Durban, South Africa
- 3eThekwini Municipality Health Unit, Durban, South Africa
- 4KwaZulu-Natal Research and Innovation Sequencing Platform (KRISP), University of KwaZulu-Natal, Durban, South Africa
- 5Department of Virology, University of KwaZulu-Natal and National Health Laboratory Service, Inkosi Albert Luthuli Central Hospital, KwaZulu-Natal, South Africa
- 6Department of Global Health, Schools of Medicine and Public Health, University of Washington, Seattle, USA
- 7Department of Medicine, School of Medicine, University of Washington, Seattle, USA
- 8Department of Epidemiology, School of Public Health, University of Washington, Seattle, USA
- 9Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa
- ↵*Corresponding Author:
Jienchi Dorward, Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG; Email: jienchi.dorward{at}phc.ox.ac.uk
Posted June 19, 2023.
Viraemia and HIV drug resistance among people receiving dolutegravir versus efavirenz-based first-line antiretroviral therapy
